AUVA Traumazentrum Vienna Site UKH Meidling

Quick facts

Phase 2 pipeline

• Intravenous Infusion of Aclasta® · Oncology
  Bisphosphonate that inhibits osteoclast-mediated bone resorption

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• AUVA Traumazentrum Vienna Site UKH Meidling portfolio CI brief
• AUVA Traumazentrum Vienna Site UKH Meidling pipeline updates RSS

Related

• Sector hub: All tracked pharma companies